Global Huntington’s Disease Market Overview
According to SPER Market Research, the Global Huntington’s Disease Market is estimated to reach USD 2.65 billion by 2032 with a CAGR of 19.83%.
The global market for Huntington's disease is expanding as a result of significant R&D expenditures for the creation of novel products, research partnerships, and the high prevalence of HD in western nations. An uncommon hereditary neurological disorder that affects multiple generations, is Huntington's disease. People in adult age are affected, which limits their ability to work, take care of their families, and finally finish everyday duties. The numbers vary between regions, which can be attributed to differences in case ascertainment and diagnostic standards. Also, the incidence varies between regions, which can be attributed to differences in case ascertainment and diagnostic standards. As a result, larger repeats may be more common than anticipated in the general population. While Europe, North America, and Australia have greater prevalence’s, the Asian population has continuously had a lower prevalence. The key players are concentrating on the research and development of HD symptomatic treatments. An investigational medication called SRX246 is being created by Azevan Pharmaceuticals to treat the neuropsychiatric signs and symptoms of Huntington's disease. The medicine SRX246 functions by obstructing the brain's vasopressin 1a (V1a) receptor.
The primary vasopressin receptor in the nervous system is the V1a receptor. By blocking the V1a receptor and preventing vasopressin from binding to the receptor, SRX246 causes the agitated and violent behaviour that is typical of people with Huntington's disease. The medications that are now approved, however, only treat the symptoms of the condition and offer palliative care. While drugs might lessen a patient's symptom intensity, they are frequently linked to side effects such as somnolence, gait problems, dysphagia, and apathy that can seriously impair a patient's quality of life. It is crucial to assess how these patients' Health-related Quality of Life (HRQOL) is affected given the lack of treatment for the illness. Early to mid-stage HD patients require integrated multidisciplinary healthcare treatments, such as counselling and assessments of cognitive function.
As a result of various medicines' inability to show effectiveness or their high levels of toxicity, drug development for HD has encountered considerable challenges. Patients with early manifest and prodromal HD did not meet the pre-specified co-primary outcomes in Vaccinex Inc.'s phase II study of pepinemab. The Huntington's disease Cognitive Assessment Battery family comprising two cognitive tests and the Clinical Global Impression of Change (CGIC) did not reach statistical significance in the SIGNAL study's early manifestation sample. Due to the availability of medicine and patent protection, the symptomatic treatment category had the highest revenue share in the last year. The entrance of SAGE-718 and Cellavita-HD is expected to make disease-modifying treatments the market sector with the fastest growth over the next years. Instead of targeting the mutant protein, businesses are now concentrating on the development of drugs that can be injected into the brain to prevent the creation of mutant HTT protein. Early-stage pharmaceuticals with innovative targets include Cellavita HD (stem cell treatment) by Cellavita and Azidus Brazil, mHTT ZFP by Sangamo Therapeutics, Inc., and AMT-130 by UniQure (gene therapy). The market for the treatment of Huntington's disease is now dominated by the symptomatic treatment sector, which also had the highest revenue share. The availability of symptom management treatments and the patent protection afforded to these medications are to blame for this rise. When it comes to first-line treatment for chorea brought on by Huntington's disease, Xenazine and Austedo are recommended.
Impact of COVID-19 on the Global Huntington’s Disease Market
The worldwide COVID-19, however, caused a slowdown in the therapy market for Huntington's disease. Antidepressants, antipsychotics, and anticonvulsants were among the off-label medications sold by online pharmacies during the epidemic to treat HD symptoms. Clinical experiments during the COVID-19 pandemic were halted because to the government shutdown.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Treatment |
| Regions covered | Asia Pacific, Europe, Middle East and Africa,North America, Latin America |
| Companies Covered | Annexon Biosciences, Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, H. Lundbeck A/S, Hetero, Hikma Pharmaceuticals PLC, Lupin, Medesis pharma SA, Mitochon Pharmaceuticals, Neurocrine bioscience Inc., Novartis, PTC Therapeutics, Inc., SOM Biotech, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., UniQure, Vaccinex, Inc. |
Global Huntington’s Disease Market Segmentation:
1. By Treatment:
- Symptomatic treatment
- Disease-modifying therapies
2. By Region:
- Asia-Pacific
- Europe
- Middle East & Africa
- North America
- South America
Key Topics Covered in the Report:- Size of Global Huntington’s Disease Market(FY’2019-FY’2032)
- Overview of Global Huntington’s Disease Market
- Segmentation of Global Huntington’s Disease Market By Treatment(Symptomatic treatment, Disease-modifying therapies)
- Statistical Snap of Global Huntington’s Disease Market
- Growth Analysis of Global Huntington’s Disease Market
- Problems and Challenges in Global Huntington’s Disease Market
- Competitive Landscape in the Global Huntington’s Disease Market
- Impact of COVID-19 and Demonetizationon Global Huntington’s Disease Market
- Details on Recent Investment in Global Huntington’s Disease Market
- Competitive Analysis of Global Huntington’s Disease Market
- Major Players in the Global Huntington’s Disease Market
- SWOT Analysis of Global Huntington’s Disease Market
- Global Huntington’s Disease Market Future Outlook and Projections (FY’2019-FY’2032)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Huntington’s Disease Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Competitive Landscape
6.1 Global Huntington’s Disease Manufacturing Base Distribution, Sales Area, Product Type
6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Huntington’s Disease Market
7. Global Huntington’s Disease Market, By Treatment, 2019-2032 (USD Million)
7.1 Symptomatic treatment
7.2 Disease-modifying therapies
8. Global Huntington’s Disease Market, By Region, 2019-2032 (USD Million)
8.1 Global Huntington’s Disease Size and Market Share by Region (2019-2025)
8.2 Global Huntington’s Disease Size and Market Share by Region (2026-2032)
8.3 Asia-Pacific
8.3.1 Australia
8.3.2 China
8.3.3 India
8.3.4 Japan
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 Europe
8.4.1 France
8.4.2 Germany
8.4.3 Italy
8.4.4 Spain
8.4.5 United Kingdom
8.4.6 Rest of Europe
8.5 Middle East and Africa
8.5.1 Kingdom of Saudi Arabia
8.5.2 United Arab Emirates
8.5.3 Rest of Middle East & Africa
8.6 North America
8.6.1 Canada
8.6.2 Mexico
8.6.3 United States
8.7 Latin America
8.7.1 Argentina
8.7.2 Brazil
8.7.3 Rest of Latin America
9. Company Profiles
9.1 Annexon Biosciences
9.1.1 Company details
9.1.2 Financial outlook
9.1.3 Product summary
9.1.4 Recent developments
9.2 Bausch Health Companies Inc.
9.2.1 Company details
9.2.2 Financial outlook
9.2.3 Product summary
9.2.4 Recent developments
9.3 Dr. Reddy's Laboratories Ltd
9.3.1 Company details
9.3.2 Financial outlook
9.3.3 Product summary
9.3.4 Recent developments
9.4 Eli Lilly And Company
9.4.1 Company details
9.4.2 Financial outlook
9.4.3 Product summary
9.4.4 Recent developments
9.5 H. Lundbeck A/S
9.5.1 Company details
9.5.2 Financial outlook
9.5.3 Product summary
9.5.4 Recent developments
9.6 Hetero
9.6.1 Company details
9.6.2 Financial outlook
9.6.3 Product summary
9.6.4 Recent developments
9.7 Hikma Pharmaceuticals PLC
9.7.1 Company details
9.7.2 Financial outlook
9.7.3 Product summary
9.7.4 Recent developments
9.8 Lupin
9.8.1 Company details
9.8.2 Financial outlook
9.8.3 Product summary
9.8.4 Recent developments
9.9 Medesis pharma SA
9.9.1 Company details
9.9.2 Financial outlook
9.9.3 Product summary
9.9.4 Recent developments
9.10 Mitochon Pharmaceuticals
9.10.1 Company details
9.10.2 Financial outlook
9.10.3 Product summary
9.10.4 Recent developments
9.11 Neurocrine bioscience Inc.
9.11.1 Company details
9.11.2 Financial outlook
9.11.3 Product summary
9.11.4 Recent developments
9.12 Novartis
9.12.1 Company details
9.12.2 Financial outlook
9.12.3 Product summary
9.12.4 Recent developments
9.13 PTC Therapeutics, Inc.
9.13.1 Company details
9.13.2 Financial outlook
9.13.3 Product summary
9.13.4 Recent developments
9.14 SOM Biotech
9.14.1 Company details
9.14.2 Financial outlook
9.14.3 Product summary
9.14.4 Recent developments
9.15 Sun Pharmaceutical Industries Ltd.
9.15.1 Company details
9.15.2 Financial outlook
9.15.3 Product summary
9.15.4 Recent developments
9.16 Teva Pharmaceutical Industries Ltd.
9.16.1 Company details
9.16.2 Financial outlook
9.16.3 Product summary
9.16.4 Recent developments
9.17 UniQure
9.17.1 Company details
9.17.2 Financial outlook
9.17.3 Product summary
9.17.4 Recent developments
9.18 Vaccinex, Inc.
9.18.1 Company details
9.18.2 Financial outlook
9.18.3 Product summary
9.18.4 Recent developments
10. List of Abbreviations
11. Reference Links
12. Conclusion
13. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
